Table 1 Predicted overall vaccine effectiveness.

From: Predicted effectiveness of vaccines and extended half-life monoclonal antibodies against RSV hospitalizations in children

Vaccination strategy

Maternal immunization (%)

Monoclonal antibodies (%)

Live-attenuated vaccines (%)

0–1 month

53 (34, 63)

58 (31, 76)

31 (11, 45)

2–3 months

40 (25, 49)

50 (25, 64)

64 (44, 79)

4–5 months

28 (17, 36)

41 (19, 54)

65 (50, 77)

6–7 months

19 (11, 25)

32 (14, 45)

66 (53, 77)

8–9 months

11 (6, 16)

24 (9, 37)

66 (54, 76)

10–11 months

4 (0, 8)

16 (3, 28)

65 (54, 76)

1 Yr

−12 (−25, −4)

−11 (−22, −2)

61 (51, 72)

2–4 Yrs

−23 (−56, −7)

−42 (−109, −20)

50 (39, 63)

<5 Yrs

24 (15, 30)

31 (15, 40)

53 (39, 64)

  1. Percentage of RSV hospitalizations averted across age groups in children under 5 years of age in the United States with coverage ranging from 85% to 95%. Medians and 95% prediction intervals are displayed.
Back to article page